Onkologie. 2022:16(3):123-126 | DOI: 10.36290/xon.2022.024
Immunotherapy in upper gastrointestinal malignancies
- Onkologické a radiologické centrum, Pardubice Multiscan, s. r. o.
- Oddělení klinické onkologie, Oblastní nemocnice Náchod
Since the introduction of the anti-CTLA4 antibody ipilimumab in 2011 in the palliative treatment of malignant melanoma with previously unprecedented results, immunotherapy has become firmly established in the treatment of a number of cancers. Given the encouraging results of immunotherapy in the first-line and the second-line setting compared to standard of care, checkpoint inhibitors (anti-CTLA-4, anti-PD1, anti-PD-L1) begin to permeate into the adjuvant setting or within the tumor-agnostic approach, including upper gastrointestinal (GI) tumors. This review offers a summary of clinical trials investigating immunotherapy with checkpoint inhibitors in the treatment of upper GI tumors.
Keywords: esophageal tumors, gastroesophageal junction tumors, gastric tumors, immunotherapy, checkpoint inhibitors.
Published: May 16, 2022 Show citation
References
- Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-249.
Go to original source... 
Go to PubMed... - Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad gastroenterologiczny. 2019;14(1):26. Go to original source... Go to PubMed...
- Then EO, et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World journal of oncology. 2020;11(2):55. Go to original source... Go to PubMed...
- SVOD. SVOD [online]. Avaible from: https://svod.cz/.
- Kelly RJ, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. New England Journal of Medicine. 2021;384(13):1191-1203. Go to original source... Go to PubMed...
- Janjigian YY, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727-730. Go to original source... Go to PubMed...
- Jangjigian YY, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27-40. Go to original source... Go to PubMed...
- Sun JM, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet. 2021;398(10302):759-771. Go to original source... Go to PubMed...
- Shitara K, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA oncology. 2020;6(10):1571-1580. Go to original source... Go to PubMed...
- Boku NMHR, et al. LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Annals of Oncology. 2020;31:S1192. Go to original source...
- Kojima T, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. Journal of Clinical Oncology. 2020;38(35): 4138-4148. Go to original source... Go to PubMed...
- Kato K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 2019;20(11):1506-1517. Go to original source... Go to PubMed...
- Shen L, et al. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. 2021. Go to original source...
- Chau I, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 stud.: Journal of Clinical Oncology. Journal of Clinical Oncology. 2021;39.Suppl.(18):LBA4001. Go to original source...
- Luo H, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. Jama. 2021;326(10):916-925. Go to original source... Go to PubMed...
- Shitara K, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2018;392(10142):123-133. Go to original source... Go to PubMed...
- Chung HCh, et al. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. 2022;128(5):995-1003.doi: 10.1002/cncr.34019. Epub 2021 Dec 8. . Go to original source... Go to PubMed...
- Thompson ED, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794-801. Go to original source... Go to PubMed...
- Derks S, et al. Epithelial PD-L2 expression marks Barrett's esophagus and esophageal adenocarcinoma. Cancer immunology research. 2015;3(10):1123-1129. Go to original source... Go to PubMed...
- Kulangara K, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Archives of pathology & laboratory medicine. 2019;143(3):330-337. Go to original source... Go to PubMed...
- Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA: a cancer journal for clinicians. 2021;71(3):264-279. Go to original source... Go to PubMed...
- Cancer genome atlas research network, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169.
- Bass AJ, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202. Go to original source... Go to PubMed...
- Choi YY, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Annals of surgery. 2019;270(2):309-316. Go to original source... Go to PubMed...
- Smyth EC, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA oncology. 2017;3(9):1197-1203. Go to original source... Go to PubMed...
- Bang YJ, et al. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncology. 2019;15(9):943-952. Go to original source... Go to PubMed...
- Al-Batran SE, et al. Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK. Annals of Oncology. 2019;30:v324. Go to original source...
- Marabelle A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology. 2020;38(1):1. Go to original source... Go to PubMed...
- Prasad V, Addeo A. The FDA approval of pembrolizumab for patients with TMB> 10 mut/Mb: was it a wise decision? Annals of Oncology. 2020;31(9):1112-1114. Go to original source... Go to PubMed...
- Catanese S, Lrodick F. Targeted and immunotherapy in the era of personalised gastric cancer treatment. Best Practice & Research Clinical Gastroenterology. 2021;50:101738. Go to original source... Go to PubMed...
- Chen Ke, et al. The Anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: a systematic review and meta-analysis and literature review. Cancer Control. 2021;28:1073274821997430. Go to original source... Go to PubMed...